 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Section 1: Introduction to the Risk-Based Approach in ICH Q1 (Draft)

Document Status and Context

What This Course Is About

Section 2: Designing and Documenting the Stability Protocol

Slide 2: Concept Simplified

Step-by-Step Actions

Preventive Actions

Section 3: Case Studies and Practical Application

Slide 3: Case Study with Characters and Dialogue

Slide 4: Practical Application

Section 4: Audit Preparation and Summary

Part C — Summary: Top 5 Takeaways

10-Point Key Audit Checklist — Risk-Based Stability Protocol Design (ICH Q1 Draft, Sec. 3.7)

Section 5: Quiz Assessment

Part A — Quiz (5 Scenario-Based Questions)

Slide 5: Knowledge Check and Takeaways

Risk Indicators (Warning Signs)

Escalation Expectations

Do and Avoid

Section 6: Feedback and Reflection

Part B — Reflection

Quality Review Confirmation

The pharmaceutical industry is undergoing a significant regulatory shift with the introduction of the new ICH Q1 (Draft) guideline. Are you prepared to navigate the complexities of risk-based stability study designs.

The pharmaceutical industry is undergoing a significant regulatory shift with the introduction of the new ICH Q1 (Draft) guideline. Are you prepared to navigate the complexities of risk-based stability study designs? Welcome to "Risk-Based Stability Study Design Under the New ICH Q1," a comprehensive online course designed to equip Regulatory Affairs, Quality Assurance, and manufacturing professionals with the critical skills needed to ensure compliance and optimize stability protocols.

This course dives deep into the specialized science- and risk-based approaches explicitly mandated in the new ICH Q1, differentiating them from generalized ICH Q9 Quality Risk Management (QRM) principles. You will learn how to strategically assess requirements, avoid compliance traps associated with blanket exemptions, and design robust, defensible stability protocols for CTD Module 3 submissions.

Through step-by-step workflows, real-world case studies, and practical applications involving technology transfers and excipient-driven reductions, you will master the art of concurrent risk documentation. Furthermore, the course provides a 10-Point Key Audit Checklist to help you proactively identify vulnerabilities and confidently defend your protocols during FDA, EMA, or PMDA inspections. Whether you are looking to shorten regulatory review cycles, prevent deficiency letters, or enhance patient safety, this course provides the actionable insights and tools you need to succeed in the evolving regulatory landscape. Enroll today to future-proof your stability study designs and ensure seamless regulatory approvals.

Risk-Based Stability Study Design Under the New ICH Q1

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The impending adoption of the new ICH Q1 (Draft) Step 2b guideline introduces a critical paradigm shift in how pharmaceutical stability studies are designed, documented, and defended. As regulatory agencies, including the FDA, EMA, and PMDA, progress toward Step 4 implementation over the next 18 to 24 months, the industry must transition from default full-testing protocols to strategically justified testing reductions. This curriculum provides a rigorous examination of the specialized science- and risk-based methodologies explicitly mandated in the new Q1 framework, carefully differentiating them from the generalized Quality Risk Management (QRM) principles outlined in ICH Q9. For Regulatory Affairs personnel constructing CTD Module 3.2.P.8 submissions and Quality Assurance reviewers approving stability protocols, mastering this evolving regulatory context is imperative to navigate inherent compliance traps, avoid blanket exemption assumptions, and prevent critical deficiency letters.</p>

<p>To operationalize these regulatory mandates, the course systematically deconstructs the specific requirements of Q1, with a focused analysis on Section 3.7 and its recursive integration into Sections 4 through 7. Validation, Manufacturing Science, and Engineering teams will engage with complex, real-world case studies to apply rigorous threshold tests for protocol reductions, particularly during multi-site technology transfers and excipient-driven scenarios. Furthermore, the program equips professionals with actionable preventive strategies, culminating in a validated 10-point audit checklist designed to evaluate internal stability protocols against the new standards. By concurrently developing robust risk documentation alongside protocol design, cross-functional teams will be fully prepared to proactively identify non-compliance vulnerabilities and confidently defend matrixed or bracketed stability decisions during stringent regulatory inspections.</p>
        </div>
    </div>
</div>
